Loading...

ARMP ARMATA PHARMACEUTICALS INC US FDA Inspections 8-K Filing

RMT

RMP

ARMATA PHARMACEUTICALS INC

(ARMP)

2026 8-K

Loan Agreement Signed

Director Appointment

Annual Meeting Notice

Financial Results Report

Financial Results Delay

FDA Approval Update

Credit Agreement Amendments

FDA Approval Progress

New Stock Offering

Financial Results Released

Positive Study Results

Corporate Presentation

Product Expansion

Financial Statements

Market Expansion

Annual Meeting Notice

Financial Results

Management Change

Management Changes

Financial Results

Study Enrollment Complete

Management Change

Management Change

Management Appointment

Financial Results

Amendment to Employment Agr...

Annual Meeting of Shareholders

Earnings Reports

Annual Meeting Announcement

Financial Results Announcement

Credit Agreement with Innov...

Promotion of Richard Rychlik

Earnings Reports

Annual Meeting Announcement

Earnings Reports

Management Changes

External Links:

On February 23, 2026, Armata Pharmaceuticals announced that the FDA granted its AP-SA02 product candidate designation as a Qualified Infectious Disease Product for treating complicated bacteremia caused by Staphylococcus aureus.

AI Assistant

ARMATA PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.